## Dong Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/781343/publications.pdf Version: 2024-02-01



DONG LIANG

#	Article	IF	CITATIONS
1	Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats. Pharmaceuticals, 2022, 15, 52.	3.8	1
2	Metabolite Identification of a Novel Anti-Leishmanial Agent OJT007 in Rat Liver Microsomes Using LC-MS/MS. Molecules, 2022, 27, 2854.	3.8	5
3	Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention. Small, 2022, 18, e2201561.	10.0	5
4	Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies. Pharmaceuticals, 2022, 15, 676.	3.8	1
5	Formulation and Characterization of O/W Nanoemulsions of Hemp Seed Oil for Protection from Steatohepatitis: Analysis of Hepatic Free Fatty Acids and Oxidation Markers. Pharmaceuticals, 2022, 15, 864.	3.8	7
6	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
7	A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. Drug Delivery, 2021, 28, 240-251.	5.7	3
8	Development and Validation of an LC–MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats. Journal of Chromatographic Science, 2021, , .	1.4	1
9	Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. Pharmaceutics, 2021, 13, 574.	4.5	3
10	Development and Validation of a Sensitive, Specific and Reproducible UPLC-MS/MS Method for the Quantification of OJT007, A Novel Anti-Leishmanial Agent: Application to a Pharmacokinetic Study. International Journal of Environmental Research and Public Health, 2021, 18, 4624.	2.6	2
11	Age-and Region-Dependent Disposition of Raloxifene in Rats. Pharmaceutical Research, 2021, 38, 1357-1367.	3.5	0
12	Glucuronides Hydrolysis by Intestinal Microbial β-Glucuronidases (GUS) Is Affected by Sampling, Enzyme Preparation, Buffer pH, and Species. Pharmaceutics, 2021, 13, 1043.	4.5	4
13	A positive–negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1179, 122854.	2.3	1
14	Development & validation of LC–MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis, 2021, 204, 114255.	2.8	4
15	Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. Biomedicine and Pharmacotherapy, 2021, 142, 112080.	5.6	25
16	Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness. Scientific Reports, 2021, 11, 2605.	3.3	2
17	Racial Disparity in Drug Disposition in the Digestive Tract. International Journal of Molecular Sciences, 2021, 22, 1038.	4.1	9
18	Development of a novel UPLC-MS/MS method for the simultaneously quantification of polydatin and resveratrol in plasma: Application to a pharmacokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 123000.	2.3	6

DONG LIANG

#	Article	IF	CITATIONS
19	Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1136, 121930.	2.3	11
20	A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study. Journal of Pharmaceutical and Biomedical Analysis, 2020, 191, 113587.	2.8	4
21	Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. Pharmaceuticals, 2020, 13, 386.	3.8	2
22	Development and validation of ultraâ€highâ€performance liquid chromatography–mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: Application to pharmacokinetic studies in rats. Journal of Separation Science, 2020, 43, 4414-4423.	2.5	6
23	<i>In Vitro</i> and <i>In Vivo</i> Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
24	<p>Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases</p> . Drug Design, Development and Therapy, 2020, Volume 14, 1263-1277.	4.3	9
25	Characterization of OJT007 and OJT008 as Inhibitors of Methionine Aminopeptidases from Mycobacterium tuberculosis. FASEB Journal, 2019, 33, .	0.5	0
26	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
27	A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases: Application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2018. 1097-1098. 35-43.	2.3	6
28	A rapid ultra-performance LC-MS/MS assay for determination of serum unbound fraction of voriconazole in cancer patients. Clinica Chimica Acta, 2018, 486, 36-41.	1.1	6
29	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
30	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
31	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
32	LC–MS/MS determination of d-mannose in human serum as a potential cancer biomarker. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 54-59.	2.8	15
33	Assessment of computer-mediated module intervention in a pharmacy calculations course. Education and Information Technologies, 2017, 22, 2013-2025.	5.7	4
34	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
35	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
36	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19

Dong Liang

#	Article	IF	CITATIONS
37	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
38	Simultaneous determination and validation of oncrasin-266 and its metabolites by HPLC–MS/MS: Application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1033-1034, 106-111.	2.3	1
39	Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharmaceutical Development and Technology, 2016, 21, 121-126.	2.4	10
40	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
41	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
42	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
43	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
44	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
45	Chemoradiation therapy using cyclopamine-loaded liquid–lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles. Journal of Controlled Release, 2015, 202, 40-48.	9.9	37
46	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
47	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
48	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Cynecologic Oncology, 2015, 136, 542-548.	1.4	15
49	The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling. Clinical Cancer Research, 2015, 21, 193-200.	7.0	51
50	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
51	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
52	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
53	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
54	Gender Differences in Pharmacokinetics of Antipyrine in a Simulated Weightlessness Rat Model. Aviation, Space, and Environmental Medicine, 2012, 83, 8-13.	0.5	9

#	Article	IF	CITATIONS
55	Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. Cancer Research, 2010, 70, 9765-9776.	0.9	118
56	Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 863, 172-176.	2.3	9